The Benefits of Being Good
This article was originally published in RPM Report
Executive Summary
Since the implementation of the PhRMA direct-to-consumer advertising guidelines in January 2006, FDA hasn't taken a single enforcement action against a consumer-directed prescription drug print or TV ad. That's good news for an industry trying to quiet critics on Capitol Hill in the run-up of the reauthorization of the Prescription Drug User Fee Act.
You may also be interested in...
Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street
The pharmaceutical industry has a lot riding on the mid-term elections: the Democrats only need to take back one chamber of Congress to do damage on Wall Street.
The New Economics of DTC: Responsibility Sells
The pharmaceutical industry's new serious tone in direct-to-consumer advertising is having an unexpected effect: commercial success. While some drug categories -- like erectile dysfunction -- may be more difficult to advertise, some marketers are finding that operating within the new voluntary guidelines makes for a more effective marketing message.
DTC Loses Powerful Friends, Will PhRMA Bring Them Back?
Direct-to-consumer advertising is being blamed in large part for the pharmaceutical industry's eroding reputation. Some of the industry's oldest friends in Congress are proposing moratoriums on DTC ads. PhRMA's DTC guidelines may have mollified Congress and FDA for now. However, with the hundreds of billions of dollars lined up for the Medicare drug benefit, CMS could be the newest player in restricting DTC.